Baseline characteristics of INTERCEPT-AD: A phase 1 trial with ACU193 targeting soluble amyloid beta oligomers for the treatment of early Alzheimer’s disease

ACU193 - Acumen Pharma

Todd Feaster , PsyD; Gopalan Sethuraman , PhD; Eric R Siemers , MD; Vladimir Skljarevski , MD; Karen L Sundell , BS; Shane Ziemba , BS

Jul 7, 2023